Novo Nordisk (NYSE: NVO) closed at $38.26 in the latest trading session, representing a gain of 1.95% against the prior day’s closing price.

The move outpaced the S&P 500, which posted a loss of 0.22% on the same day, signaling relative strength for the Danish pharmaceutical giant.

The Dow Jones Industrial Average fell 0.66% during the session, while the tech-heavy Nasdaq also declined by 0.22%, compounding a broadly negative market day.

Despite the single-session gain, Novo Nordisk shares have lost 16.9% over the past month, underperforming the Medical sector’s decline of 4.73% and the S&P 500’s gain of 1.4%.

Investors will be watching closely as the company approaches its next earnings disclosure, with analysts forecasting earnings per share of $0.80, a drop of 21.57% from the same quarter a year earlier.

Revenue expectations are equally cautious, with the current consensus estimate projecting $11.41 billion for the upcoming quarter, reflecting a 2.79% decline compared to the corresponding prior-year period.

For the full fiscal year, the Zacks Consensus Estimates call for earnings of $3.53 per share and revenue of $46.1 billion, representing year-over-year changes of -10.86% and -1.46% respectively.

Despite the downbeat annual outlook, the Zacks Consensus EPS estimate has moved 2.41% higher over the last 30 days, a signal that some analysts are incrementally more optimistic about near-term profitability.

Novo Nordisk currently holds a Zacks Rank of #3 (Hold), placing it in the middle tier of the firm’s ranking system, which spans from #1 (Strong Buy) to #5 (Strong Sell).

On valuation, NVO carries a Forward P/E ratio of 10.62, a notable discount to its industry’s average Forward P/E of 15.82, suggesting the stock may be undervalued relative to sector peers.

The company’s PEG ratio stands at 1.23, also below the Large Cap Pharmaceuticals industry average of 1.86, indicating that growth expectations are being priced in at a comparatively modest premium.

The Large Cap Pharmaceuticals industry holds a Zacks Industry Rank of 107, placing it in the top 44% of more than 250 industries tracked by the firm.

Research from Zacks shows that industries ranked in the top 50% tend to outperform the bottom half by a factor of 2 to 1, lending some broader context to where Novo Nordisk sits competitively.